Knudra in deal to use ERS Genomics' CRISPR-Cas9 gene editing IP

The USA’s Knudra Transgenics has agreed a deal with ERS Genomics which allows it to use the Ireland-based company’s CRISPR-Cas9 genome editing intellectual property for use in engineering of model organisms.

ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Emmanuelle Charpentier, an inventor of the breakthrough gene editing technology.

Financial details of the non-exclusive license agreement have not been disclosed. It will allow Knudra scientists to use CRISPR technology to engineer C. elegans, commonly known as nematodes or roundworms) and D. rerio, known as zebrafish, to build custom models and develop related products for their customers,  who are researchers and private entities.